Chai Yinghui, Li Min, Deng Xianping, Ma Congcong, Zhou Nannan, Chen Yanan, Yao Yushan, Li Kang, Gong Wenping, Lei Hong
Department of Clinical Laboratory, The Eighth Medical Center of PLA General Hospital, Beijing, China.
Graduate School, Hebei North University, Zhangjiakou, China.
Gut Microbes. 2025 Dec;17(1):2531201. doi: 10.1080/19490976.2025.2531201. Epub 2025 Jul 14.
Pulmonary tuberculosis (PTB), caused by (MTB), is a serious chronic infectious disease. Although significant progress has been made in the prevention and treatment of MTB, current anti-tuberculosis therapies still face numerous challenges. The human gut microbiota, a complex ecosystem, plays a role in host metabolism, immune regulation, and health maintenance. Recent studies have increasingly highlighted a close relationship between gut microbiota and PTB. The gut microbiota, through the gut-lung axis, mediates the immune processes of PTB, while MTB infection can disrupt the ecological balance of the gut microbiome. This review aims to summarize the changes in gut microbiota among PTB patients and their relationship with clinical manifestations, explore the role of gut microbiota in PTB immunity, and further analyze the potential application of gut microbiota therapy in PTB treatment. The goal is to provide clear direction for future research on gut microbiota and lung diseases and propose new strategies for MTB treatment.
肺结核（PTB）由结核分枝杆菌（MTB）引起，是一种严重的慢性传染病。尽管在MTB的预防和治疗方面已取得显著进展，但当前的抗结核治疗仍面临诸多挑战。人体肠道微生物群是一个复杂的生态系统，在宿主代谢、免疫调节和健康维持中发挥作用。最近的研究越来越多地强调了肠道微生物群与PTB之间的密切关系。肠道微生物群通过肠-肺轴介导PTB的免疫过程，而MTB感染会破坏肠道微生物组的生态平衡。本综述旨在总结PTB患者肠道微生物群的变化及其与临床表现的关系，探讨肠道微生物群在PTB免疫中的作用，并进一步分析肠道微生物群疗法在PTB治疗中的潜在应用。目的是为未来肠道微生物群与肺部疾病的研究提供明确方向，并提出MTB治疗的新策略。
